XML 35 R22.htm IDEA: XBRL DOCUMENT
v3.25.3

STOCK-BASED COMPENSATION | 9 Months Ended
--- | ---
Sep. 30, 2025
Equity [Abstract] |
STOCK-BASED COMPENSATION | NOTE 12 – STOCK-BASED COMPENSATION 2025 Stock Plan As discussed in Note 10, in conjunction with the digital asset treasury strategy and Private Placements, on July 16, 2025, the Company’s Board adopted the 2025 Stock Plan (the”2025 Plan”) and granted stock options to certain employees, Board members and a consultant. A total of 5,681,381 stock options were granted to purchase the Company’s common stock at $10 per share with a ten-year term, regardless of service being provided and only forfeitable in the event employment is terminated for cause as defined in the stock option agreement. These stock options vest based on the Applicable Vesting Schedule. The Company’s highest VWAP in the period from July 17, 2025 to September 30, 2025 was $29.86,and accordingly the first four tranches vested. Since these stock options are not exercisable until the 2025 Stock Plan and shares to be issued under the 2025 Stock Plan are approved by the Company’s stockholders, the Company has not recorded any share-based compensation expense for these stock options as there is no measurement date since stockholder approval is uncertain. Once stockholder approval is obtained, the Company will value these options and recognize share-based compensation for any vested awards and any unvested awards based on the derived service period. Inducement Stock Options Also in connection with the Private Placements, the Board approved 1,045,807 inducement stock option grants to purchase the Company’s common stock with an exercise price of $10 to two executives (see Note 10 above) and one employee. These stock options have a ten-year term regardless of continued employment with the Company, provided that the employee is not terminated for cause. These stock options vest based on the Applicable Vesting Schedule. The Company used a Black Scholes option pricing model and Monte Carlo simulation to value these stock options consistent with the Placement Agent Warrants (see Note 11) since the Company determined the expected life of these options is approximately 5 years. Based on the highest VWAP of the Company’s common stock since the Private Placements, 836,648 stock options have vested as of September 30, 2025. The Company recognized total expense of $8,072,716 in general and administrative expense for these inducement stock options and the remaining expense to be recognized is $1,362,555 which will be recognized over the remaining derived service period of approximately six months. In August 2024, as part of the compensation package for the Company’s Chief Sales Officer (“CSO”), the Company granted 782 stock options outside of the 2021 Plan with an exercise price of $104.32. In June 2025, the Company cancelled these stock options and paid $4,252 to the CSO. The Company recognized a net benefit of $30,932 for the share-based compensation expense previously recognized on the unvested stock options less the cash paid. 2021 Stock Plan In January 2021, the Company’s Board adopted the Volcon, Inc. 2021 Stock Plan, (the “2021 Plan”). The 2021 Plan is a stock-based compensation plan that provides for discretionary grants of stock options, stock awards, and restricted stock unit awards to employees, members of the Board and consultants (including restricted stock units issued prior to the adoption of the plan as further discussed below). The Company has reserved five shares of the Company’s common stock for issuance under the 2021 Plan. To the extent that an award, if forfeitable, expires, terminates or lapses, or an award is otherwise settled in cash without the delivery of shares of common stock to the participant, then any unpaid shares subject to the award will be available for future grant or issuance under the 2021 Plan. There are no shares available for issuance under the 2021 Plan as of September 30, 2025. Awards vest according to each agreement and as long as the employee remains employed with the Company or the consultant continues to provide services in accordance with the terms of the agreement. Other As discussed in Note 10 above, fully vested stock options were granted to one of the Company’s Co-CEOs and CFO to purchase a total of 252,525 shares of the Company’s common stock at $4.56 per share. The Company recognized share-based compensation of $1,125,802 related to these stock options in the nine months ended September 30, 2025. On July 17, 2025, the Co-CEO and CFO amended these stock options to reset the exercise price to $10 per share. There was no impact to share-based compensation for this modification as the fair value immediately after the modification was less than the fair value immediately before the modification. The following summarizes activity relating to common stock options to employees and consultants, which excludes the options granted under the 2025 Stock Plan noted above, for services during the nine months ended September 30, 2025:
Schedule of stock options activity |  |  |  |  |  |  |  |  |  |  |  |
|  | Common Stock Options |
|  | Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Life in years |  |  | Intrinsic Value |
Outstanding at January 1, 2025 |  |  | 816 |  |  | $ | 14,203.20 |  |  |  |  |  |  | $ | – |
Granted |  |  | 1,298,332 |  |  | $ | 10.00 |  |  |  |  |  |  |  |  |
Forfeited |  |  | – |  |  |  |  |  |  |  |  |  |  |  |  |
Canceled |  |  | (782 | ) |  | $ | 104.32 |  |  |  |  |  |  |  |  |
Outstanding at September 30, 2025 |  |  | 1,298,366 |  |  | $ | 121.16 |  |  |  | 9.77 |  |  |  | – |
Exercisable at September 30, 2025 |  |  | 1,089,207 |  |  | $ | 142.51 |  |  |  | 9.77 |  |  | $ | – |
Total stock-based compensation recorded for the three and nine months ended September 30, 2025 and 2024 for all stock-based compensation awards, has been recorded as follows:
Schedule of stock-based compensation expense |  |  |  |  |  |  |  |  |  |  |  |
|  | Three Months Ended September 30, 2025 |  |  | Three Months Ended September 30, 2024 |  |  | Nine Months Ended September 30, 2025 |  |  | Nine Months Ended September 30, 2024 |
Cost of goods sold |  | $ | – |  |  | $ | – |  |  | $ | – |  |  | $ | (11,827 | )
Sales and marketing |  |  | – |  |  |  | 10,053 |  |  |  | (25,132 | ) |  |  | 21,984 |
Product development |  |  | – |  |  |  | – |  |  |  | – |  |  |  | 126,337 |
General and administrative |  |  | 13,754,360 |  |  |  | – |  |  |  | 14,880,162 |  |  |  | 159,388 |
Total |  | $ | 13,754,360 |  |  | $ | 10,053 |  |  | $ | 14,855,030 |  |  | $ | 295,882 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration